NYSE:ZTS - Zoetis Stock Price, News & Analysis

$123.07
-3.57 (-2.82 %)
(As of 08/25/2019 04:00 PM ET)
Today's Range
$122.42
Now: $123.07
$127.48
50-Day Range
$113.01
MA: $118.23
$127.50
52-Week Range
$78.90
Now: $123.07
$128.41
Volume1.82 million shs
Average Volume2.00 million shs
Market Capitalization$58.77 billion
P/E Ratio39.32
Dividend Yield0.52%
Beta0.92
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.83 billion
Cash Flow$3.7080 per share
Book Value$5.05 per share

Profitability

Net Income$1.43 billion

Miscellaneous

Employees10,000
Market Cap$58.77 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.


Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Thursday, May 16th. Shareholders of record on Friday, July 19th will be paid a dividend of $0.164 per share on Tuesday, September 3rd. This represents a $0.66 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date is Thursday, July 18th. View Zoetis' Dividend History.

How will Zoetis' stock buyback program work?

Zoetis declared that its Board of Directors has authorized a stock buyback plan on Wednesday, December 12th 2018, which allows the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy up to 4.7% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) issued its earnings results on Tuesday, August, 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.82 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The business's revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.77 earnings per share. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Zoetis.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of $3.53-3.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.49. The company issued revenue guidance of $6.18-6.28 billion, compared to the consensus revenue estimate of $6.19 billion.

What price target have analysts set for ZTS?

14 analysts have issued 12 month price targets for Zoetis' shares. Their forecasts range from $86.00 to $138.00. On average, they anticipate Zoetis' stock price to reach $115.2857 in the next year. This suggests that the stock has a possible downside of 6.3%. View Analyst Price Targets for Zoetis.

What is the consensus analysts' recommendation for Zoetis?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

Has Zoetis been receiving favorable news coverage?

News coverage about ZTS stock has trended positive this week, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zoetis earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Zoetis.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest in July. As of July 31st, there was short interest totalling 3,953,400 shares, an increase of 7.7% from the June 30th total of 3,670,400 shares. Based on an average daily volume of 2,000,000 shares, the short-interest ratio is currently 2.0 days. Currently, 0.8% of the shares of the company are sold short. View Zoetis' Current Options Chain.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.68%), BlackRock Inc. (7.53%), BlackRock Inc. (7.51%), Morgan Stanley (2.78%), Polen Capital Management LLC (2.13%) and Nuveen Asset Management LLC (1.48%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

Which institutional investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including BNP PARIBAS ASSET MANAGEMENT Holding S.A., BlackRock Inc., BlackRock Inc., Mackenzie Financial Corp, AQR Capital Management LLC, Marshall Wace LLP, Marshall Wace North America L.P. and Price T Rowe Associates Inc. MD. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

Which institutional investors are buying Zoetis stock?

ZTS stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, Vanguard Group Inc., Natixis, Natixis, AKO Capital LLP, Ontario Teachers Pension Plan Board and CIBC Private Wealth Group LLC. View Insider Buying and Selling for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $123.07.

How big of a company is Zoetis?

Zoetis has a market capitalization of $58.77 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.

What is Zoetis' official website?

The official website for Zoetis is http://www.zoetis.com/.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


MarketBeat Community Rating for Zoetis (NYSE ZTS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  685 (Vote Outperform)
Underperform Votes:  420 (Vote Underperform)
Total Votes:  1,105
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel